ALTSTATION.IO

The Clorox Company (CLX) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$119.00

Change

+1.18%

Market Cap

$14.52B

Avg Volume

2.4M

Company Overview

The Clorox Company manufactures and markets a wide range of consumer and professional products globally. Headquartered in Oakland, California, Clorox operates in the Consumer Defensive sector, specifically focusing on Household and Personal Products. Its offerings include cleaning and disinfecting products, bleach, laundry additives, cat litter, food products, and personal care items. Key brands include Clorox, Pine-Sol, Glad, and Burt’s Bees, with products sold through various channels including mass retailers, grocery stores, home centers, and online platforms.

Clorox holds a strong position as a market leader in the household cleaning sector. Its well-recognized brands give it a competitive edge, particularly in cleaning and disinfecting amid heightened consumer awareness around hygiene. However, it faces significant competition from companies like Procter & Gamble and Reckitt Benckiser. Rising input costs and potential supply chain disruptions are ongoing threats, as are the dynamics of consumer preferences shifting towards sustainable and eco-friendly products.

Currently, Clorox is navigating a challenging market environment characterized by inflation and changing consumer habits. In recent quarters, the company has seen fluctuating sales, particularly as pandemic-driven demand for cleaning products normalizes. Strategic shifts toward innovation in sustainable product lines and improving operational efficiencies indicate that Clorox is pivoting to adapt to market changes. Recent investments in e-commerce capabilities suggest a move to strengthen its position amidst evolving retail dynamics.

Key Financials

Market Cap

$14.52B

Revenue

$6.76B

EBITDA

$1.23B

Gross Margin

44.2%

Profit Margin

11.2%

Revenue Growth

-0.8%

Total Cash

$227.00M

Total Debt

$3.22B

Free Cash Flow

$1.00B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

19.44

Forward P/E

17.62

Beta

0.61

52-Week High

$159.04

52-Week Low

$96.66

EPS

$6.12

50-Day Avg

$105.84

200-Day Avg

$119.06

Price/Book

-115.09

Technical Analysis

Over the past 52 weeks, Clorox Company (CLX) has shown a predominantly bearish trend, with a current price of $119.00 reflecting a -15.6% change from the previous year. Key support levels can be identified around the $110 mark, with resistance near the $140 level, indicated by the red dashed line. The chart reveals a series of lower highs and lower lows, indicating a downward trajectory, although recent price movements suggest a potential reversal as the stock has bounced back from the lows observed in December. In the last few weeks, momentum appears to be shifting upwards, with the stock approaching the resistance level at $120—recently suggesting a close at $119.00. As of now, the price is relatively low compared to the 52-week range, implying a potential undervaluation but also highlighting ongoing bearish sentiment in the stock’s longer-term performance.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for The Clorox Company (CLX) stock from February 1 to February 7, 2026:

1. Clorox Reports Mixed Q2 2026 Earnings, Reaffirms Full-Year Outlook

On February 3, 2026, The Clorox Company announced its second-quarter fiscal year 2026 results, which ended December 31, 2025. The company reported net sales of $1.67 billion, a 1% decrease, with organic sales also down 1% due to lower consumption, though partially offset by early shipments in some businesses. Diluted earnings per share (EPS) fell 16% to $1.29, and adjusted EPS decreased 10% to $1.39, missing Wall Street’s average estimate of $1.43 per share, despite revenue slightly beating forecasts. Despite the mixed results, Clorox reaffirmed its full-year fiscal 2026 outlook, expecting net sales to be down 6% to 10% and organic sales to decrease by 5% to 9%.

2. Analyst Ratings See Upgrades and Price Target Adjustments

In the past week, Clorox saw some shifts in analyst sentiment and price targets. Wall Street Zen upgraded Clorox’s rating from “sell” to “hold” on February 7, 2026. Around the same time, Morgan Stanley raised its price target for CLX to $136.00 while maintaining an “equal-weight” rating, and TD Cowen slightly increased its price target to $111.00, keeping a “hold” rating. Conversely, Deutsche Bank Aktiengesellschaft lowered its price target from $114.00 to $112.00 with a “hold” rating, and Evercore ISI reduced its price objective from $132.00 to $115.00, assigning an “underperform” rating.

Market Sentiment and Analyst Recommendations

Bull Case

Clorox is trading at 19.44x earnings while guiding for 5-9% organic sales declines, which is a reasonable multiple for a defensive consumer staple with 6.76 billion in annual revenue and a fortress balance sheet. The GOJO acquisition closing in June 2026 is a concrete catalyst that management expects to generate cost and revenue synergies, directly addressing the company’s current growth problem by adding the Purell franchise to its portfolio. The stock bounced 16.8% in the past month and is now near technical resistance at 120, suggesting institutional accumulation after the December lows, and analyst upgrades from Wall Street Zen and Morgan Stanley’s 136 price target indicate some conviction returning. Management’s innovation pipeline for H2 2026 including a new allergen-targeting cleaning platform and Glad ForceFlex relaunch shows they’re not sitting idle during a down cycle. At 119 dollars, the stock sits in the middle of the 17-analyst consensus range and only 1.2% above the average 120.47 target, meaning downside is limited relative to upside if execution improves post-acquisition.

Bear Case

Negative organic sales growth of 1% in Q2 with a full-year outlook of down 5-9% is a serious problem for a company that hasn’t found pricing power or volume growth, and the 16% EPS miss in Q2 despite beating revenue shows margin compression is real. The GOJO acquisition at 2.25 billion is debt-funded in a company already carrying 3.22 billion in total debt against only 227 million in cash, which means leverage will spike before synergies materialize and there’s execution risk on integration. The 52-week chart shows a clear downtrend with lower highs and lower lows, and while recent bounces look positive, the stock is still down 15.6% year-over-year with resistance at 140 meaning there’s limited room to run if sentiment doesn’t shift fundamentally. Evercore ISI cut its price target to 115 with an underperform rating, and Deutsche Bank lowered guidance to 112, which suggests not all analysts are convinced the turnaround narrative is real. Consumer staples are facing persistent headwinds from private label competition and e-commerce margin pressure, and Clorox’s flat innovation track record makes it unclear whether a cleaning platform or trash bag relaunch will actually move the needle on top-line growth.

What to Watch

The June 2026 GOJO acquisition close is the primary catalyst and investors should track regulatory approval progress and any deal amendments that might signal integration challenges. Q3 2026 earnings in April will be critical to confirm whether organic sales declines are stabilizing or accelerating, and any guidance raise would signal confidence in the turnaround thesis. Monitor the actual launch and sell-through data on the allergen-targeting cleaning platform and Glad ForceFlex relaunch in H2 2026 because product success will determine whether management’s innovation claims are credible. Watch the debt-to-EBITDA ratio post-acquisition close, as leverage above 3.0x would indicate the company is overleveraged and might force dividend cuts or asset sales. Track analyst price target revisions after earnings, particularly whether the recent upgrades hold or if more downgrades follow the Evercore and Deutsche Bank pattern. The 110 support level is key on the downside, and a break below it would confirm the bearish chart pattern is still intact despite recent bounces.

Analyst Consensus

HOLD

Based on 17 analyst opinions

Low Target

$94.00

Mean Target

$120.47

High Target

$163.00

Earnings and Financial Data

Sector

Consumer Defensive

Industry

Household & Personal Products

Employees

7,600

Earnings & Dividends

Next Earnings

Feb 03, 2026

EPS (Trailing)

$6.12

Dividend Yield

422.0%

Payout Ratio

80.5%

Frequently Asked Questions

Is CLX a good stock to buy?

Currently, analysts recommend a HOLD on Clorox stock, with a target price of $120.47. The stock is trading at $119.00, which suggests it may not have significant upside potential in the short term.

What is CLX’s price target?

The analyst consensus price target for Clorox is $120.47. This target indicates only a small upside from the current price of $119.00, limiting short-term investment appeal.

Does CLX pay a dividend?

Yes, Clorox has a high dividend yield of 422.0%. This makes it attractive for income-focused investors, although the sustainability of such a yield should be assessed in the context of the company’s overall financial health.

What is CLX’s P/E ratio?

Clorox has a P/E ratio of 19.44 and a forward P/E of 17.62. These figures are relatively moderate, suggesting that the stock is fairly valued compared to its earnings growth expectations.

How has CLX performed in the past year?

Clorox has traded within a 52-week range of $96.66 to $159.04. This indicates considerable volatility, and while it has potential for upside, current market conditions favor a cautious approach.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.